The Use of a Mitochondrial Enhancement Treatment in Bipolar Disorder

Status Completed

Clinical Trial Summary

The primary objective of this 15-week clinical trial is to test the hypothesis that treatment with two proven mitochondrial enhancers, acetyl-L-carnitine (ALCAR) and α-lipoic acid (ALA), has significantly greater efficacy than placebo as an augmentation treatment in bipolar depressed patients who display an incomplete response to conventional treatments.

Clinical Trial Description

The primary objective of this proposed clinical trial is to test the hypothesis that treatment with two proven mitochondrial enhancers, acetyl-L-carnitine (ALCAR) and α-lipoic acid (ALA), has significantly greater efficacy than placebo as an augmentation treatment in bipolar depressed patients who display an incomplete response to conventional treatments. We propose to test this hypothesis by performing a 15-week placebo-controlled, double-blind, parallel group, flexible-dose study investigating the use of ALCAR and ALA as an augmentation to treatment as usual in depressed bipolar patients. We will compare the efficacy of acetyl-l-carnitine (ALCAR) at doses of 1000-3000mg/day and alpha-lipoic acid (ALA) at doses of 600-1800mg/day with placebo on symptom improvement in individuals diagnosed with bipolar disorder type I, current episode depressed. Improvement will be assessed using the 21-Item Hamilton Depression Rating Scale (HAM-D), the Montgomery Asberg Depression Rating Scale (MADRS), the Young Mania Rating Scale (YMRS), and the Clinical Global Impression-Severity and Improvement Scales (CGI-S and CGI-I).

Furthermore, we hypothesize that improvement in depression symptoms following treatment with ALCAR and ALA will be associated with increases in phosphocreatine (PCr), beta-nucleoside triphosphate (β-NTP), and intracellular pH in the anterior cingulate cortex (ACC) both at week 1 and week 12 of treatment. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00719706
Study type	Interventional
Source	Mclean Hospital
Contact
Status	Completed
Phase	Phase 2
Start date	August 2008
Completion date	May 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03256162` - Ketamine as an Adjunctive Therapy for Major Depression	Phase 1
Recruiting	`NCT03396744` - Bright Light Therapy in the Treatment of Non-seasonal Bipolar Depression	Phase 1/Phase 2
Completed	`NCT01914393` - Pediatric Open-Label Extension Study	Phase 3
Active, not recruiting	`NCT03641300` - Efficacy of Convulsive Therapies for Bipolar Depression	N/A
Completed	`NCT02363738` - 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression	Phase 2
Terminated	`NCT01807741` - Asenapine for Bipolar Depression	Phase 2
Recruiting	`NCT01213121` - Neurophysiologic Changes in Patients With Bipolar Depression	Phase 4
Completed	`NCT01919892` - Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium	Phase 4
Completed	`NCT00762268` - A Trial of SAMe for Treatment-Resistant Bipolar Depression	N/A
Terminated	`NCT00566111` - Ceftriaxone in the Management of Bipolar Depression	N/A
Terminated	`NCT00217217` - Low Field Magnetic Stimulation Treatment for Bipolar Depression	Phase 3
Recruiting	`NCT04998773` - Efficacy and Biomarkers of Response of TBS in Treatment Resistant Depression	N/A
Recruiting	`NCT04939649` - Ketamine as an Adjunctive Therapy for Major Depression (2)	Phase 3
Completed	`NCT03658824` - Behavioural Activation for Bipolar Depression: A Case Series	N/A
Suspended	`NCT03674671` - Ketamine Versus Electroconvulsive Therapy in Depression	Phase 3
Recruiting	`NCT05340686` - Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression	N/A
Recruiting	`NCT05296356` - OSU6162 in Bipolar Depression (OBID)	Phase 2
Recruiting	`NCT03711019` - Efficacy of Convulsive Therapies During Continuation	N/A
Completed	`NCT02088580` - Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients	N/A
Terminated	`NCT00272025` - Treatment Resistant Bipolar Depression	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.